As Trump's unveiling of Stargate AI boosts names like Nvidia, Palantir and Broadcom, this stock screener highlights 26 ...

The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...

Shares of Ascentage Pharma Group International rose as much as 4% in the Chinese biopharmaceutical company’s US trading debut ...

Hoth Therapeutics, Inc. (HOTH) a New York-based biopharmaceutical company, Friday announced that it has been notified by Nasdaq's ...

Citigroup (C) and Evercore ISI are acting as book-running managers for the proposed IPO and as representatives of the underwriters. RBC Capital Markets and William Blair are acting as joint ...

Ascentage Pharma Group (AAPG) (AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), has priced a $126M U.S. initial public offering. The China-based drug developer priced 7.33M shares at $17.25 ...

Obesity drug developer Aardvark Therapeutics (AARD) has filed for a $100M initial public offering. Aardvark (AARD) didn't ...

Technology & Telecommunication Acquisition Corp (NASDAQ:TETE), a special purpose acquisition company, has been notified of its pending delisting from the Nasdaq Stock Market due to non-compliance with ...

The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...

When it comes to stock market debuts, 2024 was not an active year for many industries, not least cross-border payments, but ...

The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...